Medpace Holdings Inc vs Teucrium Soybean Fund — how do they compare? Medpace Holdings Inc trades at $599.14 (market cap $16.90B), while Teucrium Soybean Fund trades at $25.05. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Teucrium Soybean Fund nearer its low. Which is the better fit depends on your goals.
| MEDP | SOYB | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $620.59 | $26.28 |
52-Week Low | $393.42 | $21.46 |
Enterprise Value | $16.52B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
SOYB trades at $25.05, down 0.48% on the day, with a bearish technical bias from moving averages and neutral oscillators. Key support and resistance cluster at $25. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights agricultural sector volatility from geopolitical tensions and trade developments.
The outlook is clouded by missing financial data, though China's $17 billion U.S. crop purchase pledge through 2028 (Zacks Investment Research, 2026-05-18) offers potential tailwinds. Risks include commodity price swings from Middle East conflicts (24/7 Wall Street, 2026-07-24) and opaque company performance.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →